From DATAMONITOR Healthcare.
Recently, the US Supreme Court delivered a verdict regarding the legality of reverse payment, or ‘pay-for-delay’ settlements, in which a would-be generic manufacturer accepts payment from the patent holder in order to delay the market launch of a generic drug. This White Paper explores how the ruling will impact the dynamics of generic drug market entry.
Download the white paper. Registration is required.